Oliver H.
- Country
- Denmark
- Department
- Psychiatric Research Unit
Research Overview
- Phase III Randomized Study of AZD0486 + Rituximab versus Standard Chemoimmunotherapy in Previously Untreated Follicular Lymphoma
- Randomized, Triple‑Blind, Active‑Placebo Controlled Trial of Psilocybin (PEX010)‑Assisted Acceptance and Commitment Therapy in Treatment‑Resistant Anorexia Nervosa
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
Data & Insights
Has run more than one trial at 110 of 319 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of mantle cell lymphoma, with particular focus on developing innovative therapeutic strategies for patients with generalized disease manifestation.
- Lymphoid Malignancies
- Blood Cancer Therapies
- Hematologic Disorders
Areas of interest include novel therapeutic combinations and treatment optimization for aggressive lymphomas.
Transplantation Medicine
The investigator focuses on autologous stem cell transplantation approaches in hematologic malignancies, particularly exploring its role in lymphoma treatment protocols.
- Cell-based Therapies
- Transplant Procedures
- Post-transplant Care
Key interests include timing and sequencing of transplantation in treatment protocols.
Therapeutic Innovation
The investigator explores targeted therapy approaches in lymphoma treatment, including the integration of novel agents with conventional chemotherapy regimens.
- Combination Therapies
- Treatment Protocols
- Maintenance Strategies
Research interests encompass the development of treatment standards for aggressive lymphomas.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.